On Saturday, the 8th of September 2018, the awards gala of the "Großer Preis des Mittelstandes 2018" took place in the "International Congress Center" of the Dresden Maritim Hotel. The Berlin-based laboratory instrument manufacturer KNAUER…
A tiny change in the very flexible segments of some proteins is enough to trigger rare disorders such as Glut1 deficiency syndrome. A study published in Cell found that other genetic disorders might be traced back to the same origin.
Researchers from Charité – Universitätsmedizin Berlin and the Zuse Institute Berlin have developed a new generation of pain medications. The researchers used computer simulations to develop new opioids that will only work at sites affected by injury…
Investment in the German CRO, specialized in the preclinical assessment of new anticancer drugs, strengthens Citoxlab’s pharmacology portfolio, which will benefit from many synergies with preclinical safety and biomarkers services already provided…
Scannexus and MRI.TOOLS GmbH are delighted to announce collaboration for the
advancement of body magnetic resonance imaging (MRI). The joint project
‘MENTORA_4_EU’ has been awarded with funding from the EUROSTARS program, an EU
Horizon 2020…
Turkish researcher explores how developing life is shaped
Aydan Bulut Karslioglu, head of a research group at the Max Planck Institute for Molecular Genetics in Berlin, is one of six international scientific talents, who will receive a Sofja…
Study shows telemedicine provides benefits for patients with heart failure
Telemedical interventional management reduces hospitalisations and prolongs the life of patients with heart failure. Researchers from Charité – Universitätsmedizin Berlin…
The British Heart Foundation (BHF) will tender £30m (€33.2m) to tackle the suffering and devastation caused by heart and circulatory diseases
Start Alliance Berlin: Digital Health is a two-week program taking place in November 2018 which is intended to help startups from BEIJING, DUBAI, NEW YORK, LONDON, PARIS, SHANGHAI, TEL AVIV, VIENNA and WARSAW to expand their business to Germany via…
The biopharmaceutical company MOLOGEN AG signed, with the consent of the Supervisory Board, a term sheet outlining the framework for a global assignment of all intellectual property and other rights in MOLOGEN’s lead compound lefitolimod to ONCOLOGIE…
